We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Cytokinetics Announces Opening of a Phase IIa "Evidence of Effect" Clinical Trial of CK-2017357 in Patients with Myasthenia Gravis

News   Jan 04, 2011

 
Cytokinetics Announces Opening of a Phase IIa "Evidence of Effect" Clinical Trial of CK-2017357 in Patients with Myasthenia Gravis
 
 
Advertisement
 

RELATED ARTICLES

Children’s Immune Response Protects Them Against COVID-19 According to New Study

News

A new study compares the immune responses of adults and children with COVID-19. The study findings detected key differences that may contribute to understanding why children usually have milder disease than adults.

READ MORE

KRAS Inhibitor Sotorasib Achieves Durable Clinical Benefit in Early Trial

News

In a Phase I clinical trial for patients with advanced solid cancers marked by KRAS G12C mutations, the KRASG12C inhibitor sotorasib (AMG 510) resulted in manageable toxicities and durable clinical benefit.

READ MORE

Could Psoriatic Arthritis Be Activated by the Same Receptor in Different Patients?

News

A new study has revealed psoriatic arthritis may be activated by the same trigger in different patients. Researchers identified high levels of a specific receptor in immune cells, giving promising evidence of a single cause for the disease.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE